Status:
COMPLETED
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
Lead Sponsor:
Seqirus
Collaborating Sponsors:
Novartis Vaccines
Conditions:
Influenza
Eligibility:
All Genders
65+ years
Phase:
PHASE1
Brief Summary
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
Eligibility Criteria
Inclusion
- Subjects 65 years or older generally in good health as determined by medical history, physical assessment and clinical judgment of the investigator.
Exclusion
- Subjects who have received influenza vaccine within the past 6 month and who have received adjuvanted vaccine in the past two years.
- Subjects with hypersensitivity to vaccine components. Subjects who are on or were recently on immunosuppressive therapy.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00848848
Start Date
October 1 2008
End Date
April 1 2009
Last Update
May 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center For Vaccinology
Ghent, Belgium, 9000